Tissue Regenix Group PLC TRX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- GBX 61.50
- Day Range
- GBX 61.10–61.35
- 52-Week Range
- GBX 48.00–72.94
- Bid/Ask
- GBX 0.00 / GBX 0.00
- Market Cap
- GBX 4.34 Bil
- Volume/Avg
- 58,537 / 64,711
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 1.83
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Tissue Regenix Group PLC is a pioneering medical technology company engaged in the development of regenerative products. The company incorporates dCELL and BioRinse technology, which helps to address complex and varying clinical needs. Its product portfolio includes Biosurgery, Orthopaedics, and Dental. The company has operations around the world, with special emphasis in the United States.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 82
- Website
- https://www.tissueregenix.com
Valuation
|
Metric
|
TRX
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 4.19 |
Price/Sales | 1.83 |
Price/Cash Flow | 126.38 |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
TRX
|
|---|---|
Quick Ratio | 1.84 |
Current Ratio | 4.03 |
Interest Coverage | −0.49 |
Quick Ratio
TRX
Profitability
|
Metric
|
TRX
|
|---|---|
Return on Assets (Normalized) | −2.76% |
Return on Equity (Normalized) | −7.30% |
Return on Invested Capital (Normalized) | −0.33% |
Return on Assets
TRX
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Rrbtnxdn | Kwp | $567.0 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Mljjmdhf | Tfxzpc | $109.1 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Fpfqgrs | Ggcvwtq | $105.3 Bil | |
MRNA
| Moderna Inc | Gmpbcbgr | Ngdc | $47.0 Bil | |
ARGX
| argenx SE ADR | Kcxqgwkkr | Yxv | $22.3 Bil | |
BNTX
| BioNTech SE ADR | Zdskzyj | Cmyyg | $22.1 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Ztkkmkd | Hzfgdk | $19.0 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Nmyfnmtg | Syzbmv | $15.5 Bil | |
RPRX
| Royalty Pharma PLC Class A | Bxpmccfz | Txmdcf | $12.7 Bil | |
INCY
| Incyte Corp | Nnvwgrt | Cccymr | $12.0 Bil |